Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Reviews on Recent Clinical Trials
  4. Volume 19, Issue 4
  5. Article
Volume 19, Issue 4
  • ISSN: 1574-8871
  • E-ISSN: 1876-1038

Abstract

Objective

This study aimed to assess the efficacy and safety of anti-VEGF combined with dexamethasone implant for the retinal vein occlusion patients with macular edema.

Methods

In this prospective, case-controlled, cohort clinical trial (Register ID: ChiCTR2400080048), patients with non-ischemic retinal vein occlusion were enrolled from the Sanmenxia Central Hospital from August 2020 to April 2023. The patients were randomized into two groups. All the patients received ranibizumab intravitreal injection in the first 3 consecutive months. For the ranibizumab group, anti-VEGF injections were as needed thereafter in case of recurrence of macular edema; For the combination group, the patients received an intravitreal dexamethasone implant injection at 15 days after the first ranibizumab injection. The primary outcome measurements were improvement in best corrected visual acuity (BCVA) and reduction in central macular thickness (CMT). The secondary outcomes were recurrence of macular edema, number of intravitreal injections, and injection interval. Safety profiles were also recorded.

Results

A total of 124 patients were included, of which 73 patients completed all follow-ups. Both the ranibizumab monotherapy and the combination therapy significantly improved BCVA at all time points, compared to the baseline. The combined group achieved more BCVA improvement in 3 months, 6 months, and 12 months, compared to the ranibizumab alone group. Compared to the baseline, both groups achieved significant reductions in CMT at all follow-ups. However, the combination group showed more CMT reduction at 1 week post injection, compared to the ranibizumab group. The combination group had a significantly longer injection interval, lower injection time, and recurrence of macular edema. Ocular hypertension was the most common adverse events. Lastly, intraocular pressure was all well controlled by 1-3 glaucoma medications without surgical intervention.

Conclusion

The combination therapy could significantly improve the BCVA and reduce the CMT with a good safety profile.

Clinical Trial Study Number

ChiCTR2400080048.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/rrct/10.2174/0115748871315894240514044305
2024-05-29
2024-11-26

  • From This Site

    /content/journals/rrct/10.2174/0115748871315894240514044305
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LaouriM. ChenE. LoomanM. GallagherM. The burden of disease of retinal vein occlusion: review of the literature.Eye201125898198810.1038/eye.2011.9221546916
     [Google Scholar]
  2. IftikharM. MirT.A. HafizG. Zimmer-GallerI. ScottA.W. SolomonS.D. SodhiA. WenickA.S. MeyerleC. JiramongkolchaiK. LiuT.Y.A. ArevaloJ.F. SinghM. KheraniS. HandaJ.T. CampochiaroP.A. Loss of peak vision in retinal vein occlusion patients treated for macular edema.Am. J. Ophthalmol.2019205172610.1016/j.ajo.2019.03.02930954469
     [Google Scholar]
  3. TangY. ChengY. WangS. WangY. LiuP. WuH. The development of risk factors and cytokines in retinal vein occlusion.Front. Med.2022991060010.3389/fmed.2022.91060035783660
     [Google Scholar]
  4. AshrafM. SoukaA A R. SinghR.P. Central retinal vein occlusion: Modifying current treatment protocols.Eye201630450551410.1038/eye.2016.1026869163
     [Google Scholar]
  5. IpM.S. ScottI.U. VanVeldhuisenP.C. OdenN.L. BlodiB.A. FisherM. SingermanL.J. TolentinoM. ChanC.K. GonzalezV.H. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: The Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5.Arch. Ophthalmol.200912791101111410.1001/archophthalmol.2009.23419752419
     [Google Scholar]
  6. FengX. LiY. WuM. DanA. YangW. PengY. XiaoL. Efficacy of subthreshold micropulse laser photocoagulation therapy versus anti-vascular endothelial growth factor therapy for refractory macular edema secondary to non-ischemic branch retinal vein occlusion.J. Int. Med. Res.20235180300060523119446210.1177/0300060523119446237652453
     [Google Scholar]
  7. KumagaiK. OginoN. FukamiM. FurukawaM. Vitrectomy for macular edema due to retinal vein occlusion.Clin. Ophthalmol.20191396998410.2147/OPTH.S20321231354231
     [Google Scholar]
  8. Schmidt-ErfurthU. Garcia-ArumiJ. GerendasB.S. MidenaE. SivaprasadS. TadayoniR. WolfS. LoewensteinA. Guidelines for the management of retinal vein occlusion by the European society of retina specialists (EURETINA).Ophthalmologica2019242312316210.1159/00050204131412332
     [Google Scholar]
  9. Ghasemi FalavarjaniK. NguyenQ.D. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: A review of literature.Eye201327778779410.1038/eye.2013.10723722722
     [Google Scholar]
  10. TahV. OrlansH.O. HyerJ. CasswellE. DinN. Sri ShanmuganathanV. RamskoldL. PasuS. Anti-VEGF therapy and the retina: An update.J. Ophthalmol.2015201511310.1155/2015/62767426417453
     [Google Scholar]
  11. How It Works Available from: https://www.ozurdex.com/howitworks
  12. ChinE.K. AlmeidaD.R.P. VelezG. XuK. PeraireM. CorbellaM. ElshatoryY.M. KwonY.H. GehrsK.M. BoldtH.C. SohnE.H. RussellS.R. FolkJ.C. MahajanV.B. Ocular hypertension after intravitreal dexamethasone (Ozurdex) sustained-release implant.Retina20173771345135110.1097/IAE.000000000000136427806001
     [Google Scholar]
  13. Shibi DevB.N. SwetaV.D. SandhyaR. Secondary glaucoma after intravitreal dexamethasone implant (Ozurdex) injection in patients with retinal disorder: A retrospective study.Indian J. Ophthalmol.202270258558910.4103/ijo.IJO_684_2135086242
     [Google Scholar]
  14. AlbuainainA. Al JindanM. Al BloushiB. Surgical removal of inadvertent intralenticular sustained-release dexamethasone implant (Ozurdex) and implant one-piece posterior capsule intraocular lens.Saudi J. Ophthalmol.202034214514710.4103/1319‑4534.30504433575542
     [Google Scholar]
  15. CaiX. ZhaoJ. DangY. Combination therapy with Anti-VEGF and intravitreal dexamethasone implant for macular edema secondary to retinal vein occlusion.Curr. Eye Res.20241710.1080/02713683.2024.234305538639040
     [Google Scholar]
  16. GuX. YuX. SongS. DaiH. Intravitreal dexamethasone implant versus intravitreal ranibizumab for the treatment of macular edema secondary to retinal vein occlusion in a Chinese Population.Ophthalmic Res.201758181410.1159/00045853428334720
     [Google Scholar]
  17. DuX. ShengY. ShiY. DuM. GuoY. LiS. The efficacy of simultaneous injection of dexamethasone implant and ranibizumab into vitreous cavity on macular edema secondary to central retinal vein occlusion.Front. Pharmacol.20221384280510.3389/fphar.2022.84280535300292
     [Google Scholar]
  18. RenF. GongH. ZhangH. ZhangX. LiuX. LiJ. ZhangG. Evaluating the one-year efficacy of combined Anti-VEGF and dexamethasone implant treatment for macular edema in retinal vein occlusions.Med. Sci. Monit.202329e93927737301978
     [Google Scholar]
  19. GaoL. ZhouL. TianC. LiN. ShaoW. PengX. ShiQ. Intravitreal dexamethasone implants versus intravitreal anti-VEGF treatment in treating patients with retinal vein occlusion: A meta-analysis.BMC Ophthalmol.2019191810.1186/s12886‑018‑1016‑730621640
     [Google Scholar]
  20. ZhangM. LiuY. SongM. YuY. RuanS. ZhengK. WangF. SunX. Intravitreal dexamethasone implant has better retinal perfusion than anti-vascular endothelial growth factor treatment for macular edema secondary to retinal vein occlusion: A five-year real-world study.Ophthalmic Res.202366124725810.1159/00052744736215955
     [Google Scholar]
  21. LiangX. ShenB. OuZ. AnH. LiL. Comparison of intravitreal ranibizumab monotherapy vs. ranibizumab combined with dexamethasone implant for macular edema secondary to retinal vein occlusion.Front. Med.2022993050810.3389/fmed.2022.93050836172537
     [Google Scholar]
  22. CoscasG. AugustinA. BandelloF. de SmetM.D. LanzettaP. StaurenghiG. ParravanoM.C. UdaondoP. MoisseievE. SoubraneG. YatzivY. LoewensteinA. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion.Eur. J. Ophthalmol.20142411910.5301/ejo.500037624249150
     [Google Scholar]
  23. QuerquesL. QuerquesG. LattanzioR. GiganteS.R. Del TurcoC. CorradettiG. CascavillaM.L. BandelloF. Repeated intravitreal dexamethasone implant (Ozurdex®) for retinal vein occlusion.Ophthalmologica20132291212510.1159/00034216023006995
     [Google Scholar]
  24. YeY. HuangZ. WuQ-W. HuiY-N. SongY-P. SongY.P. Long-term outcomes of anti-VEGF treatment with 5+PRN regimen for macular edema due to central retinal vein occlusion.Int. J. Ophthalmol.202316101642165010.18240/ijo.2023.10.1337854371
     [Google Scholar]
  25. KishoreK. BhatP.V. VenkateshP. CanizelaC.C. Dexamethasone intravitreal implant for the treatment of macular edema and uveitis: A comprehensive narrative review.Clin. Ophthalmol.2022161019104510.2147/OPTH.S20939535418744
     [Google Scholar]
  26. SimsekM. CitirikM. OzatesS. OzkoyuncuD. The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario.Indian J. Ophthalmol.201866683183610.4103/ijo.IJO_1259_1729785994
     [Google Scholar]
  27. Chang-LinJ.E. BurkeJ.A. PengQ. LinT. OrillaW.C. GhosnC.R. ZhangK.M. KuppermannB.D. RobinsonM.R. WhitcupS.M. WeltyD.F. Pharmacokinetics of a sustained-release dexamethasone intravitreal implant in vitrectomized and nonvitrectomized eyes.Invest. Ophthalmol. Vis. Sci.20115274605460910.1167/iovs.10‑638721421864
     [Google Scholar]
  28. XuS. SongZ. LiG. ZhangC. Antivascular endothelial growth factor for macular oedema secondary to retinal vein occlusion: A systematic review and meta-analysis.BMJ Open Ophthalmol.202271e00108610.1136/bmjophth‑2022‑001086
     [Google Scholar]
/content/journals/rrct/10.2174/0115748871315894240514044305
Loading
Safety and Efficiency of Anti-VEGF with Dexamethasone Intravitreal Implant for Non-Ischemic Retinal Vein Occlusion: A Prospective, Case-controlled, Cohort Study
Rev. Recent Clin. Trials 19, 280 (2024); https://doi.org/10.2174/0115748871315894240514044305
/content/journals/rrct/10.2174/0115748871315894240514044305
/content/journals/rrct/10.2174/0115748871315894240514044305
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Research Article
Keyword(s): adverse event; best corrected visual acuity; central macular thickness; ranibizumab group; retinal vein occlusion; Vascular endothelial growth factor

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test